Clinical trial · Observational
Predictive Value of FMISO-PET, FDG-PET-CT, DWI-MRI and DCE-MRI Scans for Patients With Anal Cancer Receiving Radiotherapy +/- Chemotherapy
18F-FMISO-PET, 18F-FDG-PET/CT, DWI-MRI and DCE-MRI Scans as Predictors of Response to Radiotherapy +/- Chemotherapy in Patients With Anal Cancer.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to evaluate the predictive value of 18F-fluoromisonidazol-PET (FMISO-PET), 2-18F-fluoro-2-deoxy-d-glukose-PET-CT (FDG-PET-CT), Diffusion-Weighted Magnetic Resonance Imaging (DWI-MRI) and Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) for patients with anal cancer receiving radiation therapy +/- chemotherapy (Cisplatin and 5-FU).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anal Cancer | Malignant Anal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Anal cancer
- interventionNames
- Other: FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI)
Primary outcomes (1)
- measure
- Tumor response
- timeFrame
- 6-8 weeks post radiation
- description
- * Primary tumor 18-F-deoxyglucose (FDG) uptake before radiation and during week 3 of radiation. * Primary tumor apparent diffusion coefficient before radiation and during week 3 of radiation and 6-8 weeks post radiation * Primary tumor perfusion coefficient before radiation and during week 3 of radiation and 6-8 weeks post radiation * Primary tumor 18-F-Fluoromisonidazol (FMISO) uptake before radiation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological confirmation of invasive primary squamous cell carcinoma of the anal canal or perianal region. * TNM stage T1-4, N0-3, M0-1 * Treatment with curative intent * Age \> 18 years * Able to provide informed consent Exclusion Criteria: * Contraindication to MRI imaging * Cardiac pacemaker * Major obesity * Serious claustrophobia * Other malignant disease (except non-melanoma skin cancer) in a period of 5 years prior to imaging study * Poorly regulated diabetes mellitus despite insulin * Pregnancy * Breast feeding * Known allergy to iv contrast agent * Major psychiatric illness which would prevent participation in the imaging study * Infectious wounds on the legs * Unacceptable kidney function * Major language difficulties which would prevent participation in the imaging study
References
Publications (0)
Data not yet available